Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.65 |
| ▸ | DPP4 | P27487 | 4/20 | 0.65 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.65 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.65 |
| ▸ | FAP | Q12884 | 1/20 | 0.65 |
| ▸ | ACE | P12821 | 2/20 | 0.54 |
| ▸ | REN | P00797 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2123080 | 1.00 | DPP7 (0.65) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL27796855 | 1.00 | DPP7 (0.65) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL2113410 | 1.00 | DPP7 (0.65) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL2113409 | 1.00 | DPP7 (0.65) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL29374265 | 1.00 | DPP7 (0.65) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL2113944 | 0.96 | DPP4 (0.59) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL29610030 | 0.96 | DPP4 (0.59) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL2113947 | 0.96 | DPP4 (0.59) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL11017609 | 0.95 | DPP7 (0.60) | DPP7DPP4DPP8DPP9FAP | |
| SCHEMBL10829152 | 0.95 | DPP7 (0.60) | DPP7DPP4DPP8DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| CN-119015834-A | Carbon dioxide separation membrane and preparation method thereof | 国家能源投资集团有限责任公司 | 2024-11-26 | — | — | CN | claimed |
| EP-0618235-B1 | Process for the synthesis of semisynthetic glycosaminoglycans containing alpha-L-galacturonic acid substituted with nucleophilic radicals in position 3 | ALFA WASSERMANN SPA (IT) | 1997-07-23 | — | — | EP | claimed |
| EP-0565862-B1 | Semi-synthetic glycosaminoglycans containing alpha-L-galacturonic acid substituted with nucleophilic radicals in position 3 | ALFA WASSERMANN SPA (IT) | 1997-06-18 | — | — | EP | claimed |
| EP-0565863-B1 | Semi-synthetic glycosaminoglycans with heparin or heparan structure of alpha-L-iduronic-2-0-sulfate acid modified in position 2 | ALFA WASSERMANN SPA (IT) | 1997-06-18 | — | — | EP | claimed |
| EP-0618234-B1 | Process for the synthesis of semisynthetic glycosaminoglycans with heparin or heparan structure modified in position 2 of the alpha-L-iduronic-2-0-sulfate acid | ALFA WASSERMANN SPA (IT) | 1997-06-04 | — | — | EP | claimed |
| US-5430133-A | Semi-synthetic glycosaminoglycans with heparin or heparan structure of α-L-iduronic-2-O-sulfate acid modified in position 2 | ALFA WASSERMANN S.P.A. (IT) | 1995-07-04 | — | — | US | claimed |
| US-5410039-A | Process for the synthesis of glycosaminoglycans containing α-L-galacturonic acid substituted with nucleophilic groups in position 3 | ALFA WASSERMANN S.P.A. (IT) | 1995-04-25 | — | — | US | claimed |
| US-5405949-A | Process for the synthesis of glycosaminoglycans with heparin or heparan structure modified in position 2 of the α-L-iduronic-2-O-sulfate acid | ALFA WASSERNANN S.P.A. (IT) | 1995-04-11 | — | — | US | claimed |
| EP-0618235-A1 | Process for the synthesis of semisynthetic glycosaminoglycans containig alpha-L-galacturonic acid substituted with nucleophilic radicals in position 3 | ALFA WASSERMANN S.p.A. (IT) | 1994-10-05 | — | — | EP | claimed |
| EP-0618234-A1 | Process for the synthesis of semisynthetic glycosaminoglycans with heparin or heparan structure modified in position 2 of the alpha-L-iduronic-2-0-sulfate acid | ALFA WASSERMANN S.p.A. (IT) | 1994-10-05 | — | — | EP | claimed |
| EP-0565863-A2 | Semi-synthetic glycosaminoglycans with heparin or heparan structure of alpha-L-iduronic-2-0-sulfate acid modified in position 2 | ALFA WASSERMANN S.p.A. (IT) | 1993-10-20 | — | — | EP | claimed |
| EP-0565862-A2 | Semi-synthetic glycosaminoglycans containing alpha-L-galacturonic acid substituted with nucleophilic radicals in position 3 | ALFA WASSERMANN S.p.A. (IT) | 1993-10-20 | — | — | EP | claimed |
| US-4786737-A | PREPARATION OF TUFTSIN AND LISINOPRIL | AJINOMOTO CO., INC. (JP) | 1988-11-22 | — | — | US | claimed |
| EP-3526196-B1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) | 2026-03-10 | — | — | US | disclosed |
| EP-4702045-A1 | GLUCOSE SENSITIVE INSULIN DERIVATIVES | Novo Nordisk A/S (DK) | 2026-03-04 | — | — | EP | disclosed |
| EP-0292708-A2 | Detection of Bacteroides gingivalis | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1988-11-30 | — | — | EP | disclosed |
| US-4786737-A | PREPARATION OF TUFTSIN AND LISINOPRIL | AJINOMOTO CO., INC. (JP) | 1988-11-22 | — | — | US | disclosed |
| US-4720554-A | Aromatic sulfonic acid salts of a proline derivative | AJINOMOTO CO., INC. (JP) | 1988-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | SERPINH1, HM13, NGLY1 | DPP7 545/4885DPP4 671/4885DPP8 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.